Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00551642
Recruitment Status : Completed
First Posted : October 31, 2007
Results First Posted : October 18, 2010
Last Update Posted : December 21, 2016
Information provided by (Responsible Party):

October 30, 2007
October 31, 2007
September 3, 2010
October 18, 2010
December 21, 2016
May 2005
February 2008   (Final data collection date for primary outcome measure)
  • Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress [ Time Frame: 36 weeks gestational age ]
    The primary outcome was determined by assessment of survival and incidence of BPD,which was defined by the need for supplemental oxygen at 36 weeks gestational age (GA); an infant who was alive without BPD at 36 weeks GA was counted as success; an infant who died or had BPD at 36 weeks GA was counted as a failure.
  • Survival [ Time Frame: 36 Weeks GA ]
Chronic Lung Disease [ Time Frame: 36 weeks GA ]
Complete list of historical versions of study NCT00551642 on Archive Site
  • Vital Signs [ Time Frame: Study Duration ]
  • Arterial Oxygen Saturation by Pulse Oximetry [ Time Frame: Study Duration ]
  • Adverse Events [ Time Frame: Study Duration ]
  • Methemoglobin Level [ Time Frame: Baseline, then 24 hours, 2-6 days, Day 7 and Day 14 of treatment ]
Days of assisted ventilation; Length of hospitalization; Survival without IVH and PVL; Days in hospital for respiratory illness fron 36 wks GA to 1 and 2 years corrected age; Safety outcomes [ Time Frame: two years ]
Not Provided
Not Provided
Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants
The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to assess the long-term effects of the therapy on the development of these children over 7 years of clinical follow-up.
Although the effects of inhaled Nitric Oxide on pulmonary vascular tone are well-described and relevant to term infants with persistent pulmonary hypertension, the pathophysiology of respiratory failure in preterm infants may be quite different. Chronic lung disease (CLD) represents the final pathway of a heterogeneous group of pulmonary disorders of infancy that usually start in the neonatal period. CLD most commonly occurs in preterm (<30 weeks of gestational age (GA) infants with birth weights less than 1,500 g, and especially in those very preterm (<26 wks GA) with birth weights less than 1,000 g, and who have been treated for respiratory distress syndrome (RDS).
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Lung Disease
  • Drug: Nitric Oxide for inhalation
    inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
    Other Name: INOmax®
  • Drug: Nitrogen
    nitrogen gas given at 5ppm for 7-21 days
  • Group A
    24+0-25+6 days weeks gestational age
    • Drug: Nitric Oxide for inhalation
    • Drug: Nitrogen
  • Group B
    26+0 - 28+6 days weeks Gestational Age
    • Drug: Nitric Oxide for inhalation
    • Drug: Nitrogen

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2015
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first trimester ultrasound or if not available based on the last menstrual period) who requires the use of surfactant within 24 hours of birth (either prophylactically, or for signs of developing respiratory distress), or who requires the use of continuous positive airway pressure (CPAP) (fraction of inspired oxygen concentration (FiO2) ≥ 0.30 on a mean airway pressure ≥ 4cm water (H2O)) within 24 hours of birth in order to maintain an oxygen saturation (SpO2) ≥ 85%.
  • Informed consent of the guardian.

Exclusion Criteria:

  • Outborn infants.
  • Infants ≥ 29 weeks gestational age.
  • Infants requiring FiO2 >0.5 to maintain SpO2 >85%, on a sufficient mean airway pressure (e.g., > 8 cm H2O on controlled mechanical ventilation (CMV)) in order to achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper administration of exogenous surfactant.
  • Any suspected congenital heart disease other than patent ductus arteriosus or atrial septal defect.
  • Any infant with severe bleeding or coagulation abnormalities at high-risk of diathesis, e.g., platelet <50,000/mm³, fibrinogen <0.5 g/L, other clotting factors <10%.
  • Any infant in whom a decision has been made not to provide full treatment, e.g., chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.
  • Use of another investigational drug or device before or during the active study period.
Sexes Eligible for Study: All
up to 26 Hours   (Child)
Contact information is only displayed when the study is recruiting subjects
Belgium,   Finland,   France,   Germany,   Italy,   Netherlands,   Spain,   Sweden,   United Kingdom
EUNO, EU Preemie
Not Provided
Not Provided
Not Provided
Study Chair: Jean-Christophe Mercier Hospital Robert Debre
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP